Vericel Corp Company Profile (NASDAQ:VCEL)

About Vericel Corp (NASDAQ:VCEL)

Vericel Corp logoVericel Corporation, formerly Aastrom Biosciences, Inc., is a commercial-stage biopharmaceutical company dedicated to the identification, development and commercialization of therapies that enable the body to repair and regenerate damaged tissues and organs to restore normal structure and function. The Company operates through the research, product development, manufacture and distribution of patient-specific, expanded cellular therapies for use in the treatment of specific diseases segment. Its autologous cell therapy products include Carticel (autologous cultured chondrocytes), which is an autologous chondrocyte implant for the treatment of cartilage defects in the knee, and Epicel (cultured epidermal autografts), which is a permanent skin replacement for the treatment of patients with deep-dermal or full-thickness burns. The Company is developing MACI, which is a third-generation autologous chondrocyte implant and ixmyelocel-T, which is a patient-specific multicellular therapy.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Symbol: NASDAQ:VCEL
  • CUSIP: N/A
  • Web: www.aastrom.com
Capitalization:
  • Market Cap: $90.11 million
  • Outstanding Shares: 32,766,000
Average Prices:
  • 50 Day Moving Avg: $2.63
  • 200 Day Moving Avg: $2.72
  • 52 Week Range: $1.96 - $4.55
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -5.98
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $49.64 million
  • Price / Sales: 1.82
  • Book Value: $0.47 per share
  • Price / Book: 5.85
Profitability:
  • EBIDTA: ($22,390,000.00)
  • Net Margins: -34.31%
  • Return on Assets: -52.60%
Debt:
  • Current Ratio: 1.37%
  • Quick Ratio: 1.14%
Misc:
  • Average Volume: 265,668 shs.
  • Beta: 2.85
  • Short Ratio: 3.22
 

Frequently Asked Questions for Vericel Corp (NASDAQ:VCEL)

What is Vericel Corp's stock symbol?

Vericel Corp trades on the NASDAQ under the ticker symbol "VCEL."

How were Vericel Corp's earnings last quarter?

Vericel Corp (NASDAQ:VCEL) released its quarterly earnings results on Wednesday, May, 10th. The company reported ($0.31) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.19) by $0.12. The company had revenue of $9.36 million for the quarter. View Vericel Corp's Earnings History.

Where is Vericel Corp's stock going? Where will Vericel Corp's stock price be in 2017?

2 equities research analysts have issued 1 year price objectives for Vericel Corp's shares. Their predictions range from $6.00 to $6.00. On average, they expect Vericel Corp's stock price to reach $6.00 in the next twelve months. View Analyst Ratings for Vericel Corp.

Are investors shorting Vericel Corp?

Vericel Corp saw a decline in short interest in April. As of April 13th, there was short interest totalling 1,722,949 shares, a decline of 4.7% from the March 31st total of 1,808,420 shares. Based on an average daily trading volume, of 244,386 shares, the short-interest ratio is presently 7.1 days.

Who are some of Vericel Corp's key competitors?

Who owns Vericel Corp stock?

Vericel Corp's stock is owned by a number of of institutional and retail investors. Top institutional investors include Stonepine Capital Management LLC (9.98%), Vanguard Group Inc. (3.44%), Perkins Capital Management Inc. (0.70%), Geode Capital Management LLC (0.67%), Renaissance Technologies LLC (0.25%) and KCG Holdings Inc. (0.14%). View Institutional Ownership Trends for Vericel Corp.

Who sold Vericel Corp stock? Who is selling Vericel Corp stock?

Vericel Corp's stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC and KCG Holdings Inc.. View Insider Buying and Selling for Vericel Corp.

Who bought Vericel Corp stock? Who is buying Vericel Corp stock?

Vericel Corp's stock was purchased by a variety of institutional investors in the last quarter, including Stonepine Capital Management LLC, Vanguard Group Inc. and Geode Capital Management LLC. View Insider Buying and Selling for Vericel Corp.

How do I buy Vericel Corp stock?

Shares of Vericel Corp can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Vericel Corp stock cost?

One share of Vericel Corp stock can currently be purchased for approximately $2.75.

Analyst Ratings

Consensus Ratings for Vericel Corp (NASDAQ:VCEL) (?)
Ratings Breakdown: 2 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $6.00 (118.18% upside)

Analysts' Ratings History for Vericel Corp (NASDAQ:VCEL)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
3/13/2017Needham & Company LLCReiterated RatingBuy -> Buy$9.00 -> $6.00HighView Rating Details
12/22/2016Piper Jaffray CompaniesInitiated CoverageOverweight$6.00N/AView Rating Details
4/5/2016Bank of America CorpDowngradeBuy -> NeutralN/AView Rating Details
3/12/2016Ladenburg Thalmann Financial ServicesReiterated RatingBuyN/AView Rating Details
(Data available from 5/23/2015 forward)

Earnings

Earnings History for Vericel Corp (NASDAQ:VCEL)
Earnings by Quarter for Vericel Corp (NASDAQ:VCEL)
Earnings History by Quarter for Vericel Corp (NASDAQ:VCEL)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/10/2017Q1 2017($0.19)($0.31)$9.36 millionViewN/AView Earnings Details
11/7/2016Q3($0.28)($0.38)$10.93 millionViewListenView Earnings Details
5/10/2016Q116($0.25)($0.08)$11.60 million$14.10 millionViewListenView Earnings Details
3/14/2016Q415($0.15)($0.28)$17.36 million$15.40 millionViewListenView Earnings Details
11/13/2015Q315($0.21)($0.26)$10.50 million$11.30 millionViewListenView Earnings Details
8/12/2015Q215($0.13)($0.16)$11.31 million$13.60 millionViewListenView Earnings Details
5/14/2015Q115($0.14)($0.27)$11.10 million$10.80 millionViewListenView Earnings Details
3/23/2015Q414($0.47)($0.17)$10.70 million$14.70 millionViewListenView Earnings Details
11/13/2014Q314($0.66)($0.52)$6.73 million$9.66 millionViewN/AView Earnings Details
8/14/2014Q214($1.59)($0.94)$2.50 million$4.43 millionViewN/AView Earnings Details
5/15/2014Q114($0.92)($1.26)ViewN/AView Earnings Details
3/13/2014Q413($1.34)($0.97)$0.02 million$0.01 millionViewN/AView Earnings Details
11/12/2013Q3($2.02)($0.06)ViewListenView Earnings Details
5/8/2013Q1 2013($0.19)($0.15)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Vericel Corp (NASDAQ:VCEL)
Current Year EPS Consensus Estimate: $-0.80 EPS
Next Year EPS Consensus Estimate: $-0.46 EPS

Dividends

Dividend History for Vericel Corp (NASDAQ:VCEL)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Vericel Corp (NASDAQ:VCEL)
Insider Ownership Percentage: 2.40%
Institutional Ownership Percentage: 24.31%
Insider Trades by Quarter for Vericel Corp (NASDAQ:VCEL)
Institutional Ownership by Quarter for Vericel Corp (NASDAQ:VCEL)
Insider Trades by Quarter for Vericel Corp (NASDAQ:VCEL)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
3/28/2016Consonance Capital ManagementMajor ShareholderSell120,000$5.39$646,800.00View SEC Filing  
9/16/2014Daniel OrlandoCOOBuy9,804$2.55$25,000.20View SEC Filing  
9/16/2014Dominick ColangeloCEOBuy20,000$2.55$51,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Vericel Corp (NASDAQ:VCEL)
Latest Headlines for Vericel Corp (NASDAQ:VCEL)
Source:
DateHeadline
finance.yahoo.com logoEdited Transcript of VCEL earnings conference call or presentation 10-May-17 12:00pm GMT
finance.yahoo.com - May 12 at 3:44 AM
americanbankingnews.com logoVericel Corp (VCEL) Releases Quarterly Earnings Results, Misses Estimates By $0.12 EPS
www.americanbankingnews.com - May 11 at 4:26 PM
seekingalpha.com logoVericel's (VCEL) CEO Nick Colangelo on Q1 2017 Results - Earnings Call Transcript
seekingalpha.com - May 11 at 3:03 AM
finance.yahoo.com logoVericel Licenses Product Portfolio to Innovative Cellular Therapeutics for Distribution in China, South Korea, and other Countries in Southeast Asia
finance.yahoo.com - May 10 at 10:00 AM
finance.yahoo.com logoVericel Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Ixmyelocel-T for the Treatment of Advanced Heart Failure Due to Ischemic Dilated Cardiomyopathy
finance.yahoo.com - May 10 at 10:00 AM
finance.yahoo.com logoVericel Reports First-Quarter 2017 Financial Results
finance.yahoo.com - May 10 at 10:00 AM
finance.yahoo.com logoInvestor Network: Vericel Corporation to Host Earnings Call
finance.yahoo.com - May 10 at 10:00 AM
americanbankingnews.com logoVericel Corp (VCEL) Expected to Announce Earnings of -$0.19 Per Share
www.americanbankingnews.com - May 8 at 1:12 PM
americanbankingnews.com logoVericel Corp (VCEL) Scheduled to Post Quarterly Earnings on Monday
www.americanbankingnews.com - May 6 at 7:04 AM
finance.yahoo.com logoVericel to Host First-Quarter 2017 Earnings Webcast and Conference Call on May 10, 2017
finance.yahoo.com - May 5 at 3:10 AM
americanbankingnews.com logoVericel Corp (VCEL) Getting Somewhat Negative Press Coverage, Report Shows
www.americanbankingnews.com - April 30 at 9:04 AM
americanbankingnews.com logoShort Interest in Vericel Corp (VCEL) Drops By 4.7%
www.americanbankingnews.com - April 29 at 7:18 PM
globenewswire.com logoVericel to Present at the 5th Annual Cell & Gene Therapy Investor Day - GlobeNewswire (press release)
globenewswire.com - April 21 at 8:30 PM
americanbankingnews.com logo Analysts Anticipate Vericel Corp (VCEL) to Post -$0.19 Earnings Per Share
www.americanbankingnews.com - April 17 at 3:06 PM
finance.yahoo.com logoVericel Announces Appointment of Michael Halpin as Senior Vice President, Quality and Regulatory Affairs
finance.yahoo.com - April 10 at 8:00 PM
finance.yahoo.com logoETFs with exposure to Vericel Corp. : April 7, 2017
finance.yahoo.com - April 7 at 6:21 PM
finance.yahoo.com logoVericel to Present at the 16th Annual Needham Healthcare Conference
finance.yahoo.com - March 28 at 8:29 AM
us.rd.yahoo.com logoOutcomes Data From Over 950 Severe Burn Patients Treated With Epicel Presented at the 49th Annual Meeting of the American Burn Association
us.rd.yahoo.com - March 23 at 3:50 PM
americanbankingnews.com logoVericel Corp’s (VCEL) “Buy” Rating Reiterated at Needham & Company LLC
www.americanbankingnews.com - March 17 at 9:29 AM
baystreet.ca logoVericel Corp (VCEL) Gains Despite Projected Loss
www.baystreet.ca - March 11 at 11:33 PM
seekingalpha.com logoVericel's (VCEL) CEO Nick Colangelo on Q4 2016 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - March 11 at 9:58 AM
us.rd.yahoo.com logoVericel Reports Fourth-Quarter and Year-End 2016 Financial Results
us.rd.yahoo.com - March 10 at 10:08 AM
biz.yahoo.com logoVERICEL CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
biz.yahoo.com - March 10 at 10:08 AM
seekingalpha.com logoVericel (VCEL) Presents At Cowen and Company 37th Annual Health Care Conference - Slideshow
seekingalpha.com - March 9 at 4:10 AM
feeds.benzinga.com logoVericel to Host Fourth-Quarter 2016 Earnings Webcast and Conference Call on March 10, 2017
feeds.benzinga.com - March 3 at 8:22 AM
bizjournals.com logoBiotech Stocks Under Scanner -- Immunomedics, Peregrine Pharma, Vericel, and Biogen
www.bizjournals.com - March 1 at 9:02 AM
finance.yahoo.com logoVericel to Present at Multiple Upcoming Investor Conferences
finance.yahoo.com - February 27 at 5:19 PM
streetinsider.com logoVericel (VCEL) Announces Receipt of FDA Fast Track Designation for Ixmyelocel-T
www.streetinsider.com - February 21 at 4:25 PM
us.rd.yahoo.com logoVericel Receives FDA Fast Track Designation for Ixmyelocel-T, an Investigational Product for the Treatment of Patients with Advanced Heart Failure Due to Ischemic Dilated Cardiomyopathy
us.rd.yahoo.com - February 21 at 4:25 PM
us.rd.yahoo.com logo7:31 am Vericel: FDA has designated the investigation of ixmyelocelT for reduction in the risk of death and cardiovascular hospitalization in patients with chronic advanced heart failure due to ischemic dilated cardiomyopathy as a Fast Trac
us.rd.yahoo.com - February 21 at 4:25 PM
streetinsider.com logoVericel (VCEL) Reports First MACI Implant in U.S. for Treatment of Symptomatic Cartilage Defects of the Knee - StreetInsider.com
www.streetinsider.com - February 2 at 6:32 AM
finance.yahoo.com logo7:02 am Vericel announces the first implant of MACI in the US for the repair of symptomatic single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults
finance.yahoo.com - February 2 at 6:32 AM
finance.yahoo.com logoVericel Announces First MACI Implant in the United States for the Treatment of Symptomatic Cartilage Defects of the Knee
finance.yahoo.com - February 1 at 7:17 AM
biz.yahoo.com logoVERICEL CORP Files SEC form 8-K/A, Entry into a Material Definitive Agreement, Financial Statements and Exhibits
biz.yahoo.com - January 4 at 7:33 AM
finance.yahoo.com logoCoverage initiated on Vericel by Piper Jaffray
finance.yahoo.com - December 23 at 3:46 AM
finance.yahoo.com logoVericel Corporation Announces Exercise of Underwriters’ Over-Allotment Option and Closing of $20 Million Offering of Common Stock
finance.yahoo.com - December 21 at 8:24 PM

Social

Chart

Vericel Corp (VCEL) Chart for Tuesday, May, 23, 2017

This page was last updated on 5/23/2017 by MarketBeat.com Staff